WebFeb 14, 2024 · PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated the safety and activity of T-DXd in patients with advanced HER2 … WebMay 4, 2024 · Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials. Interstitial lung disease and pneumonitis are important risks requiring careful monitoring and prompt …
Trastuzumab Deruxtecan in Previously Treated HER2-Positive ... - PubMed
WebJan 8, 2024 · Two new treatment options are emerging for women with metastatic breast cancer, following positive results from clinical trials. The trials tested the drugs tucatinib and trastuzumab deruxtecan ( Enhertu) in women who had been previously treated for metastatic breast cancer that overproduces the HER2 protein, known as HER2-positive … WebDec 11, 2024 · 612 n engl j med 382;7 nejm.orgFebruary 13, 2024 The new england journal of medicine were randomly assigned in a 1:1:1 ratio to re-ceive trastuzumab … trier amphitheatre
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast …
WebDec 11, 2024 · Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a … WebJul 7, 2024 · Patients with HER2-low breast cancer have limited targeted treatment options for progressing disease after primary therapy. An antibody–drug conjugate has sh... WebJun 5, 2024 · On August 5, 2024, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical … trier all you can eat